Page 1,522«..1020..1,5211,5221,5231,524..1,5301,540..»

The Telegraph | Alton Memorial Hospital’s diabetes program … – Alton Telegraph

Posted: June 30, 2017 at 12:44 pm

ALTON Alton Memorial Hospitals Diabetes Management office has earned the prestigious American Diabetes Association Education Recognition Certificate. The ADA believes that this program offers high-quality education that is an essential component of effective diabetes treatment.

The Associations Education Recognition Certificate assures that educational programs meet the national standards for diabetes self-management education programs.

The process gives professionals a national standard by which to measure the quality of services we provide, said Lisa James, diabetes educator at AMH. And, of course, it assures the consumer that he or she will receive high-quality service.

Education Recognition status is verified by an official certificate from ADA and awarded for four years.

Self-management education is an essential component of diabetes treatment. One consequence of compliance with the national standards is the greater consistency in the quality and quantity of education offered to people with diabetes. The participant in a recognized program will be taught, as needed, self-care skills that will promote better management of his or her diabetes treatment regimen. All approved education programs cover the following topics as needed: diabetes disease process; nutritional management; physical activity; medications;

monitoring; preventing, detecting, and treating acute complications; preventing, detecting, and treating chronic complications through risk reduction; goal setting and problem solving; psychological adjustment; and preconception care, management during pregnancy, and gestational management.

Unnecessary hospital admissions and some of the acute and chronic complications of diabetes may be prevented through self-management education.

According to the American Diabetes Association, there are 29.1 million people or 9.3 percent of the population in the United States who have diabetes. While an estimated 21 million people have been diagnosed, 8.1 million people are not aware that they have this disease. Each day more than 3,900 people are diagnosed with diabetes. Many will first learn that they have diabetes when they are treated for one of its life-threatening complications heart disease and stroke, kidney disease, blindness, and nerve disease and amputation.

For more information about diabetes education at Alton Memorial, call Lisa James at 618-463-7526.

James

http://thetelegraph.com/wp-content/uploads/2017/06/web1_Lisa-James.jpgJames

.

More here:
The Telegraph | Alton Memorial Hospital's diabetes program ... - Alton Telegraph

Posted in Diabetes | Comments Off on The Telegraph | Alton Memorial Hospital’s diabetes program … – Alton Telegraph

Director General of Nigeria’s biotechnology agency arrested over N23 million fraud – Premium Times

Posted: June 29, 2017 at 11:43 am

The Economic and Financial Crimes Commission, EFCC, says it has arrested Lucy Ogbadu, the Director-General of National Biotechnology Development Agency (NABDA), over alleged N23 million fraud.

The spokesperson of the commission, Wilson Uwujaren, disclosed this in a statement he issued on Thursday.

Mr. Uwujaren said Ms. Ogbadu was picked up by EFCC operatives in Port Harcourt on Wednesday, following her alleged link with the Bayelsa State Director of Bio-resources Development Centre, Josiah Habu.

Mr. Habu, according to him, is being investigated by the anti-graft agency in a case of fraudulent diversion of N75 million.

He said investigations by the EFCC revealed that Ms. Ogbadu allegedly received N23 million through a bank account belonging to the wife of Mr. Habu, Esther Habu.

The EFCC spokesperson stated that Ms. Ogbadu admitted the transaction in a voluntary statement made to the commissions investigators.

Further investigations also revealed that Mrs Habu is one of the contractors with Bio-resources Development Centre, Odi, Bayelsa State.

A total of N603 million has been traced to her in different deals involving over 20 directors of the centre across the country.

Ogbadus involvement is being investigated. She has been duly served with bail conditions while investigations continue, Mr. Uwujaren added.

Ms. Ogbadu, a professor of microbiology, was appointed NABDA director-general in November 2013.

(NAN)

More here:
Director General of Nigeria's biotechnology agency arrested over N23 million fraud - Premium Times

Posted in Biotechnology | Comments Off on Director General of Nigeria’s biotechnology agency arrested over N23 million fraud – Premium Times

Puma Biotechnology (PBYI) Earns Slightly Unfavorable Press Analysis, Based On In-Depth Analysis – Insider Tradings

Posted: June 29, 2017 at 11:43 am

Press articles about Puma Biotechnology (NYSE:PBYI) has been popular fairly negative last few days, Accern reports. The analytics team pointing out the bullish and bearish news analysis by observing larger than 20 Million public financial documents, market websites and SEC sources in real-time. Accern grades analysis of public companies ranging from -1 to 1, with ranks nearest to 1 is considered more positive. Puma Biotechnology achieved a news impact rank of -0.01 on Accerns range. Accern issued stories about the biopharmaceutical company a media impact point of 66 out of 100, pointing that recent news analysis is likely to impact the share value upcoming future.

Puma Biotechnology (NYSE:PBYI) previously disclosed its earnings report on early Wed, May 10th. The biopharmaceutical business posted ($1.97) Earnings per share for the period, reaching the Thomson Reuters average forecast of ($2.06) by $0.09. Brokerage firms predict that Puma Biotechnology to post ($8.50) earnings per share for the full year.

Puma Biotechnology (NYSE:PBYI) transacted up 4.71% throughout intraday market trading on early Wed, topping $88.85. the share had a trading volume of 872,030 Stocks. Puma Biotechnology has a 52 week low of $27.64 and a 52 week high of $92.00. The stocks market valuation is $3.28 B. Companys 50 Day SMA is $59.74 and its 200 day SMA is $42.39.

PBYI has been the topic of many Study analysis. Citigroup boosted Puma Biotechnology to a buy recommendation and fixed a $105.00 target price for The corporation in a study note on Sunday, May 28th. Zacks Lowered Puma Biotechnology from a buy recommendation to a hold recommendation in a analysis note on early Wed, Jun 14th. Stifel Nicolaus reiterated a buy recommendation and fixed a $105.00 target price on stock of Puma Biotechnology in a study note on early Mon, Jun 5th. J P Morgan Chase & Co reissued an overweight recommendation and fixed a $89.00 target price on stock of Puma Biotechnology in a study note on early Tue, Jun 6th. Lastly, Royal Bank Of Canada boosted their target price on Puma Biotechnology from $60.00 to $88.00 and issued the shares a sector perform recommendation in a analysis note on Tue, Jun 6th. 1 investment expert has recommended the share with a sell recommendation, two have published a hold recommendation and six have published a buy recommendation to The corporation. Puma Biotechnology currently has a average recommendation of Buy and an consensus price target of $86.94.

In other Puma Biotechnology news, large stockholder Adage Capital Partners Gp, L.L unloaded 507,128 stocks of the firms shares in a trade on early Mon, Jun 5th. The stock was unloaded at a price range of of $87.84, amounting $44,546,123.52. The information was declared in a transaction filed with the securities and exchange commission, which is available through the Security and Exchange Commission website. executive have unloaded 1,990,088 stocks of company shares valued $157,553,113 during the last ninety days. Executives own 22.70% of the firms stock.

Read more here:
Puma Biotechnology (PBYI) Earns Slightly Unfavorable Press Analysis, Based On In-Depth Analysis - Insider Tradings

Posted in Biotechnology | Comments Off on Puma Biotechnology (PBYI) Earns Slightly Unfavorable Press Analysis, Based On In-Depth Analysis – Insider Tradings

Hebrew U Isolates ‘Haploid’ Human Stem Cells, Changing Future of Medicine – The Jewish Press – JewishPress.com

Posted: June 29, 2017 at 11:42 am

Photo Credit: Hebrew University

A Stem cell research milestone was reached last year, when Ido Sagi, working as a PhD student at the Hebrew University of JerusalemsAzrieli Center for Stem Cells and Genetic Research, led research that yielded the first successful isolation and maintenance of haploid embryonic stem cells in humans.

Unlike in mice, these haploid stem cells were able to differentiate into many other cell types, such as brain, heart and pancreas, while retaining a single set of chromosomes.

Stem cell research holds huge potential for medicine and human health. In particular, human embryonic stem cells (ESCs), with their ability to turn into any cell in the human body, are essential to the future prevention and treatment of disease.

Most of the cells in our body are diploid, which means they carry two sets of chromosomes one from each parent. Until now, scientists have only succeeded in creating haploid embryonic stem cells which contain a single set of chromosomes in non-human mammals such as mice, rats and monkeys. However, scientists have long sought to isolate and replicate these haploid ESCs in humans, which would allow them to work with one set of human chromosomes as opposed to a mixture from both parents.

Together with Prof. Nissim Benvenisty, Director of the Azrieli Center, Sagi showed that this new human stem cell type will play an important role in human genetic and medical research. It will aid our understanding of human development for example, why we reproduce sexually instead of from a single parent. It will make genetic screening easier and more precise, by allowing the examination of single sets of chromosomes. And it is already enabling the study of resistance to chemotherapy drugs, with implications for cancer therapy.

Based on this research,Yissum, the Technology Transfer arm of the Hebrew University, launched the company New Stem, which is developing adiagnostic kit for predicting resistance to chemotherapy treatments. By amassing a broad library of human pluripotent stem cells with different mutations and genetic makeups, NewStem plans to develop diagnostic kits for personalized medication and future therapeutic and reproductive products.

In recognition of his work, Ido Sagi was awarded the Kaye Innovation Award for 2017.

The Kaye Innovation Awards at the Hebrew University of Jerusalem have been awarded annually since 1994. Isaac Kaye of England, a prominent industrialist in the pharmaceutical industry, established the awards to encourage faculty, staff and students of the Hebrew University to develop innovative methods and inventions with good commercial potential, which will benefit the university and society.

Ido Sagi received BSc summa cum laude in Life Sciences from the Hebrew University, and currently pursues a PhD at the laboratory of Prof. Nissim Benvenisty at the universitys Department of Genetics in the Alexander Silberman Institute of Life Sciences. He is a fellow of the Adams Fellowship of the Israel Academy of Sciences and Humanities, and has recently received the Rappaport Prize for Excellence in Biomedical Research. Sagis research focuses on studying genetic and epigenetic phenomena in human pluripotent stem cells, and his work has been published in leading scientific journals, including Nature, Nature Genetics and Cell Stem Cell.

Go here to see the original:
Hebrew U Isolates 'Haploid' Human Stem Cells, Changing Future of Medicine - The Jewish Press - JewishPress.com

Posted in Cell Medicine | Comments Off on Hebrew U Isolates ‘Haploid’ Human Stem Cells, Changing Future of Medicine – The Jewish Press – JewishPress.com

Scientists Manipulate ‘Signaling’ Molecules to Control Cell Migration – Bioscience Technology

Posted: June 29, 2017 at 11:42 am

Johns Hopkins researchers report they have uncovered a mechanism in amoebae that rapidly changes the way cells migrate by resetting their sensitivity to the naturally occurring internal signaling events that drive such movement. The finding, described in a report published online March 28 in Nature Cell Biology, demonstrates that the migratory behavior of cells may be less hard-wired than previously thought, the researchers say, and advances the future possibility of finding ways to manipulate and control some deadly forms of cell migration, including cancer metastasis.

"In different tissues inside the body, cells adopt different ways to migrate, based on their genetic profile and environment," says Yuchuan Miao, a graduate student at the Johns Hopkins University School of Medicine and lead author of the study. "This gives them better efficiency to perform specific tasks." For example, white blood cells rhythmically extend small protrusions that allow them to squeeze through blood vessels, whereas skin cells glide, like moving fans, to close wounds.

On the other hand, Miao notes, uncontrolled cell migration contributes to diseases, including cancer and atherosclerosis, the two leading causes of death in the United States. The migration of tumor cells to distant sites in the body, or metastasis, is what kills most cancer patients, and defective white blood cell migration causes atherosclerosis and inflammatory diseases, such as arthritis, which affects 54 million Americans and costs more than $125 billion annually in medical expenditures and lost earnings.

Because cells migrate in different ways, many drugs already designed to prevent migration work only narrowly and are rarely more than mildly effective, fueling the search for new strategies to control migratory switches and treat migration-related diseases, according to senior author Peter Devreotes, Ph.D., a professor and director of the Department of Cell Biology at the Johns Hopkins University School of Medicines Institute for Basic Biomedical Research.

People have thought that cells are typed by the way they look and migrate; our work shows that we can change the cell's migrating mode within minutes, adds Devreotes.

For the new study, Devreotes and his team focused on how chemical signaling molecules activate the motility machinery to generate protrusions, cellular feet that are a first step in migration. To do this, they engineered a strain of Dictyostelium discoideum, an amoeba that can move itself around in a manner similar to white blood cells. The engineered amoebae responded to the chemical rapamycin by rapidly moving the enzyme Inp54p to the cell surface, where it disrupted the signaling network. The cells also contained fluorescent proteins, or markers, that lit up and showed researchers when and where signaling molecules were at work.

Experiments showed that the engineered cells changed their migration behavior within minutes of Inp54p recruitment. Some cells, which the researchers termed oscillators, first extended protrusions all around the cell margins and then suddenly pulled them back again, moving in short spurts before repeating the cycle. Fluorescent markers showed that these cycles corresponded to alternating periods of total activation and inactivation, in contrast to the small bursts of activity seen in normal cells.

Other cells began to glide as fans, with a broad zone of protrusions marked by persistent signaling activity.

Devreotes describes the signaling behavior at the cell surface as a series of waves of activated signaling molecules that switch on the cellular motility machinery as they spread. In their normal state, cells spontaneously initiated signaling events to form short-lived waves that made small protrusions.

In contrast, oscillators had faster signaling waves that reached the entire cell boundary to generate protrusions before dying out. Fans also showed expanded waves that continually activated the cell front without ever reaching the cell rear, resulting in wide, persistent protrusions.

The scientists say their experiments show that the cell movement changes they saw resulted from lowering the threshold level of signaling activity required to form a wave. That is, cells with a lower threshold are more likely to generate waves and, once initiated, the activation signals spread farther with each step.

Devreotes says the teams experimental results offer what appears to be the first direct evidence that waves of signaling molecules drive migratory behavior. Previously, his laboratory showed a link between signaling and migration, but had not specifically examined waves.

In further experiments, Devreotes and his team found that they could recruit different proteins to shift cell motility, suggesting, he says, that altering threshold is a general cell property that can change behaviorno matter how cells migrate. His team was also able to restore normal motility to fans and oscillators by blocking various signaling activities, suggesting new targets for drugs that could be designed to control migration.

Devreotes cautions that what happens in an amoeba may not have an exact counterpart in a human cell, but studies in his lab suggest that something like the wave-signaling mechanism they uncovered operates in human cells as well.

The bottom line, says Miao, is that we now know we can change signaling wave behavior to control the types of protrusions cells make. When cells have different protrusions, they have different migratory modes. When we come to understand the essential differences between cells migratory modes, we should have better ways to control them during disease conditions.

Follow this link:
Scientists Manipulate 'Signaling' Molecules to Control Cell Migration - Bioscience Technology

Posted in Cell Medicine | Comments Off on Scientists Manipulate ‘Signaling’ Molecules to Control Cell Migration – Bioscience Technology

Siberian scientists say stem cells can treat varicose veins – Russia Beyond the Headlines

Posted: June 29, 2017 at 11:42 am

Scientists at the Institute of Chemical Biology and Fundamental Medicine (ICBFM) based in Siberia have discovered that stem cells can restore blood flow in veins with clots.

Facebook

Pinterest

WhatsApp

"Quite a lot of pathologies regarding veins still remain unstudied." Source: Getty Images

To help treat varicose veins, scientists need to accelerate the growth of blood vessels, which would be a crucial development for cardiac medicine. A heart attack is caused by damaged arteries, and an ischemic stroke also often results from vascular damage.

"Quite a lot of pathologies regarding veins still remain unstudied," said Igor Mayborodin, a doctor of medical sciences at the stem cell laboratory at ICBFM. "Weve looked into blood flow restoration in situations when there are blood clots. Now were trying to use stem cells to stimulate the growth of veins and bypass the diseased area."

The discovery by Siberian scientists will make it possible to successfully treat diseases of the veins and resulting complications, for example, varicosis, phlebothrombosis (the formation of a blood clot in the vein that leads to its blockage), and even some types of trophic ulcers and cerebral strokes.

Researchers conducted a number of studies on rats, injecting them with stem cells taken from their relatives. The experiment showed that within a week small vessels had formed in the rodents, and in the third week the replacement of the introduced cells with the rodents' own cells began.

The new blood vessels remained in the body but stem cells that formed walls were gradually replaced by those of the rodents. Thus, scientists showed that stem cells can restore blood flow, bypassing damaged veins. Based on the results, a series of articles will be prepared.

Also, scientists witnessed unexpected side effects. "Some of the stem cells die, and then macrophages are attracted to the site, that is, 'ingester' cells capable of actively engulfing and digesting the remains of dead cells," Mayborodin said. "This is what helps a surgical wound be rid of damaged tissue quicker and heal. This is a good result."

The scientists are continuing their state-funded research, and they have obtained a patent for their work. For the time being, however, they cant check the results in clinical tests because Russian law restricts the use of stem cells on humans.

"Wed like to utilize the obtained data in regards to humans, but this is currently not possible," Mayborodin said. "For now were refining the results of the research on cell therapy and clarifying possible complications. But wed like to test our hypothesis at least on a severe case of varicosis in clinical conditions."

Continue reading here:
Siberian scientists say stem cells can treat varicose veins - Russia Beyond the Headlines

Posted in Cell Medicine | Comments Off on Siberian scientists say stem cells can treat varicose veins – Russia Beyond the Headlines

AML: Cellectis testing allogenic CAR-T cell therapy – European Biotechnology

Posted: June 29, 2017 at 11:41 am

Genome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia.

The company said it enrolled the first patient with acute myeloid leukaemia (AML) to be treated with UCART123 at Weill at Cornell Medicine, New York Presbyterian Hospital. UCART123 is a TALEN-genome edited chimeric T cell receptor targeting the CD123/IL3R antigen on the surface of blasts and dendric cells, which is administered on allogeneic donor T cells. The team of Gail J. Roboz will investigate the safety and will collect first indications for efficacy of UCART123 in patients with AML. The Phase I trial is part of a strategic translational research alliance that was formed between Cellectis and Weill Cornell Medicine in 2015.

While Novartis AG and Kite Pharma are leading the CAR-T cell therapy development in AML, Cellectis hopes to overtake its competitors. It has the only approach that works with allogenic CAR-engineered T cells that could be centrally pre-manufactured in contrast to the autologous patient T cells. Those need to be isolated, engineered and expanded during the at least 14 day hospital stay of the patients to be treated making the procedure costly, lengthy and laborious. On the other hand, Cellectis therapy does not target the CD19 T cell antigen but CD123//IL3R giving the company another unique selling point.

Cellectis has used TALEN technology to block expression of the TCRa constant (TRAC) gene though blocking expression of the natural TCR. According to Andr Choulika, Cellectis CEO, TALEN technology shows less off-target effects compared to CRISPR/Cas9 genome editing. Following apheresis, donor T cells are engineered to express an anti-CD123 CAR (CD123 scFv-41BB-CD3z) and an RQR8 depletion ligand that confers susceptibility to rituximab. Theoretically, specifity of of UCART123 therapy might be higher in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) than in patients with AML as CD123 expression is 10fold higher in the precursors of plasmacytoid dendritic cells than in blast occurring in the course of AML.

Cellectis also announced two new entries to ists Board of Directors. Ex-Novartis pharma division head Rainer Boehm will lead commercialisation of Cellectis lead candidate. Ex Novartis Oncology President and Incyte Corp CEO Herv Hoppenot will lead clinical development.

Go here to read the rest:
AML: Cellectis testing allogenic CAR-T cell therapy - European Biotechnology

Posted in Cell Therapy | Comments Off on AML: Cellectis testing allogenic CAR-T cell therapy – European Biotechnology

New approach in T-cell therapy to treat cancer – Scientist Live

Posted: June 29, 2017 at 11:41 am

With numerous different entities and millions of people affected, cancer continues to be one of the most prevalent diseases around the world.

Scientists are working to find new treatment possibilities, and have been concentrating on the bodys own immune system for some time.

Because cancer emerges from the bodys own cells, it is usually difficult for the immune system to distinguish good cells from bad ones, explains Prof Dr Elfriede Nner, head of the Tissue Control of Immunocytes Research Group at the Helmholtz Zentrum Mnchen. But there are ways to support the immune system in recognizing and combating cancer cells.

Focus on T-cell therapy

One approach is the so-called adoptive T-cell therapy, which involves removing immune cells from the body and genetically arming them.

The cells are given new structures on the surface that accurately lead them to the cancer cells.

One limitation in this form of therapy is that the binding between the immune cell and the cancer cell is often somewhat weak.

Although this binding can be artificially strengthened, doing so also increases the risk of unwanted binding to healthy structures in the body, explains study leader Nner. She and her team were therefore searching for a different way to improve the defence provided by the immune cells.

Attack instead of sleep mode

In the current work, the researchers present a new surface molecule which comprises two halves.

On the outside, it preferentially binds to the PD-L1 molecule, which tumour cells often form in order to thwart the attacking immune cells.

On the inside of the T-cells, however, this binding does not activate a sleep mode (which the natural protein would do), and instead activates the T-cells killer programme, making it especially aggressive.

Experimental models showed that T-cells armed in this way proliferate more strongly in the tumours and destroyed more tumour cells.

The next step will be to confirm the findings in clinical studies.

If that step succeeds, the approach would enlarge the arsenal of T-cells suitable for adoptive T-cell therapy, Elfriede Nner states. This could not only make the treatment more effective but would allow it to be used in more patients in the framework of personalised medicine.

The work was the result of close cooperation with the team headed by Dr. Matthias Leisegang from the Institute of Immunology at the Charit Berlin Buch Campus and Prof Dr Dolores J Schendel, CEO and CSO at Medigene AG. The authors Ramona Schlenker, Luis Felipe Olguin Contreras, Anja Disovic and Julia Schnappinger attend the Helmholtz Graduate School Environmental Health, or HELENA for short.

Original Publication: Schlenker, R. et al. (2017): Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumour-infiltrating lymphocytes for adoptive cell therapy. Cancer Research, DOI: 10.1158/0008-5472.CAN-16-1922

The rest is here:
New approach in T-cell therapy to treat cancer - Scientist Live

Posted in Cell Therapy | Comments Off on New approach in T-cell therapy to treat cancer – Scientist Live

Is Sangamo Therapeutics Pointing Toward Success? – Seeking Alpha

Posted: June 29, 2017 at 11:41 am

Sangamo Therapeutics (SGMO) is a $650 million dollar market cap company focused on gene and cell therapies, including conducting the first-ever genome editing studies in clinical trials. The company uses gene therapy, genome editing, cell therapy, and gene regulation techniques to develop novel therapies. In gene therapy, attenuated Adeno-Associated Viral ((NYSE:AAV)) delivery systems are employed to carry functional gene copies to patients suffering from an ineffective or absent protein causing a disease state, such as in Hemophilia A (in collaboration with Pfizer (NYSE:PFE). The company is developing genome editing technologies for Hemophilia B and various lysosomal storage disorders, employing zinc finger nucleases (ZFN) to knock out harmful, defective, or unwanted proteins and also to insert helpful donor genes. The company is also utilizing gene editing and cell therapy techniques (T cell and stem cell) to treat HIV, and is partnering with Bioverativ (BIVV) to develop stem cell treatments for beta-thalassemia and sickle cell disease. Cell therapy can be used in conjunction with ZFN technology after harvesting afflicted cells, treating, testing for desired effects, cultured, then reinfused into the patient. Because ZFPs are the most common DNA binding motif in transcription factors of eukaryotic systems, gene repression or activation systems can be generated. SGMO is pursuing in central nervous system afflictions such as Huntington's Disease (in collaboration with Shire (SHPG)), by using specific gene repression of mutant disfunctional HTT gene but leaving functional gene products unchanged. Sangamo is attacking Alzheimer's and various tauopathies utilizing the same approaches. The company is also advancing non-therapeutic technologies with Sigma-Aldrich Corporation and Dow AgroScience.

Pfizer is a leading developer of AAV-based technologies. SGMO and Pfizer's collaboration in hemophilia A in May 2017 to develop AAV-based drug candidate gene therapy SB-525, one of Sangamo's four lead drug candidates, has received orphan drug status and fast track from FDA and EMA, and was perceived by the market as a big boost of confidence for Sangamo. The stock is up over 100% since the announcement. Pfizer made an initial payment of $70 million with up to $475 million in potential milestones, with $175 million potential for additional gene therapies if opted by Pfizer. Mikael Dolsten, president of worldwide research and development at Pfizer, stated, "We believe SB-525 has the potential to be a best-in-class therapy" that could provide stability to patients "with a single administration treatment." SGMO ZFN technology had recently been overshadowed in market sentiment by next-generation genome-editing technologies such as CRISPR prior to the announcement.

The company announced in the first quarter 2017 that it had received orphan drug designation (ODD, previously attained) and fast track designation from FDA for genome editing treatment SB-FIX for Hemophilia B. SGMO also progressed in lysosomal disorders by obtaining Rare Pediatric Disease Designation for in vivo genome editing treatment SB-318 for MPS I. In this disorder a deficiency in alpha-L iduronidase results in toxic buildup of glycosaminoglycans. According to the 2017 first quarterly report, "a sponsor who receives approval for a new drug application or biologics license application may be eligible to receive a voucher for a priority review of a subsequent marketing application for a different product. The voucher may be used by the sponsor or sold or transferred." SB-318 had also previously received ODD. The company also received ODD and Rare Pediatric Disease Designation for in vivo genome editing treatment SB-913 for MPS II (Hunter's disease). In this disorder, iduronate-2-sulfatase deficiency results in the buildup of glycosaminoglycans as well.

Sangamo's ZFN-mediated genome editing program for sickle cell disease and beta-thalassemia hemoglobinopathies transferred to Bioverativ in November of 2016, as part of a 2014 deal with Biogen. Bioverativ spun off from Biogen in early 2017 as a separate entity with specific experts to handle transformation of therapies for these rare diseases. Experts in related blood diseases hemophilia A and B medications will oversee sales and marketing of its lead products ELOCTATE and ALPROLIX respectively, as part of the responsibilities of the company.

Sangamo is using ZFN-mediated genome editing in the HIV space as well. Sangamo Therapeutics' approach inserts a naturally occurring human mutation which renders individuals largely resistant to HIV into T-cells and is monitoring patients in an open label phase 2 trial. Sangamo's SB-728-T HIV drug candidate targets the most common form of HIV. A Phase 1/2 clinical trial is also being conducted to evaluate safety and efficacy of its stem cell candidate, SB-728-HSPC, in HIV patients.

At the preclinical level, in vitro human culture and animal model data demonstrated significant reduction of tau mRNA and tau protein expression using ZFP transcription factor-mediated gene regulation technology. Results from the laboratory studies were presented at the 13th International Conference on Alzheimer's & Parkinson's Diseases.

Sangamo recently raised approximately $72 million in a public offering June 21, 2017, at $7.25 per share. An analyst at Jefferies was recently impressed by the company's presentation at a conference, and set a $17 per share price target on the SGMO shares. The company says it plans to use the funds to develop genomic therapy product candidates and potentially acquire complementary businesses, technologies, or licenses. Additionally the analyst said that this stock can serve as a financial investment hedge against the emerging gene-editing technology of CRISPR.

The gene editing and cell therapy spaces are definitely unproven to some extent and risky. There is also competitive risk in that this company is going up against some of the best regarded technologies in a tough field of gene and cell therapies that are possibly further advanced, including CRISPR. However, the risks are higher for Alzheimer's and HIV than for more straight-forward indications such as Hemophilia A. Pfizer's $70 million stamp of approval should reinforce that argument. Given the high quality partnerships for SGMO and relatively diverse pipeline, the reward to risk ratio should be adequate for a long position at these prices. The company is still in early to mid-stage trials, but a breakthrough in a rare or fatal indication could be an inflection point for the stock.

As of end Quarter one the company estimated $132 million in cash, taken with the recent offering of ~$70 million and estimated quarterly burn rate of ~$30 million leaves about $170 million in cash. This is a significant cash runway but given the immaturity of the clinical trial pipeline it is hard to predict if more dilution will be necessary in coming years. With only about $3 million in quarterly revenues trickling in its doubtful that the company can go without diluting if something were to go wrong. However, with its nice strategic partnerships and potential milestones from Pfizer, if things go well in the Hemophilia A project the company could near a cash neutral position within a couple of years.

Strong Bio regards this stock as a great watchlist stock, with intent to invest on significant pullbacks over time. Future clinical trial updates that indicate novel and robust responses could indicate FDA breakthrough therapy designation-worthy therapies. Of particular interest to Strong Bio are the projects of Alzheimers, HIV and cancer, as they have potential to show strong benefit in large markets. However, waiting too long might put investors in a "pay over the top" position as the more lead project Hemophilia A, B, and HIV projects progress. Strong Bio targets an entry in the $6.75 range.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read more here:
Is Sangamo Therapeutics Pointing Toward Success? - Seeking Alpha

Posted in Cell Therapy | Comments Off on Is Sangamo Therapeutics Pointing Toward Success? – Seeking Alpha

Fighting Diabetes With Food – Fortune

Posted: June 29, 2017 at 11:40 am

In the summer of 2012, Sami Inkinen was 36, wealthy, and semiretired. Trulia, the online real estate company he cofounded and nurtured from a startup to a business with some 20 million users, had filed to go public, and he had decided to cease his operational role. The eight-year journey had been rewarding but exhausting. Inkinen planned to focus on angel investing.

That would leave plenty of time for his main hobby: triathlons. A champion who obsessively tracks his biometrics, Inkinen was a fitness freak even by Silicon Valley standards. He had less than 8% body fat.

But life is full of ironic twists, and he was hurtling toward a particularly sharp one. Soon after Trulia went public, Inkinen noticed something strange: His blood sugar levels were above normal and rising. He was prediabetic.

Inkinen skipped the doctor and began researching on his own. After discovering a decades-old paper that showed Type 2 diabetes can be prevented and sometimes reversed through lifestyle changes alone, he switched to a low-carbohydrate, high-fat diet. As his blood sugar levels dropped, his excitement spiked.

This spring he took his mission even further: Inkinen launched Virta Health , a 60-person startup backed by $37 million in funding. The service combines Inkinens passiona data-heavy appwith the same medical approach that he credits with reversing his prediabetes. Virta is one of a handful of companies attempting to attack the epidemicsome 28 million Americans suffer from Type 2 diabeteswithout relying on medications.

Researchers long believed Type 2 diabetes was not curable, but today the prevailing view is that it can be reversed by weight loss, says Dr. George King, the chief scientific officer at Joslin Diabetes Center and a professor at Harvard Medical School.

More: A New Innovation for Type 2 Diabetes

In that sense, Inkinen is an improbable advocate. He seemed like an unlikely candidate to be heading toward Type 2 diabetes in the first place. A native of Finland, Inkinen was always very active, but his seemingly healthy diet was packed with sugar (in the form of fruit smoothies) and carbs (five bowls of oatmeal a day). After diagnosing himself as prediabetic, he abruptly cut back on carbs and sugar. (Today hes an evangelist for a ketogenic diet, the food trend of the moment in Silicon Valley. It embraces high-fat foods and limits carbs to less than 50 grams a day, the equivalent of a cup of brown rice.)

Inkinen credits that diet for fueling an epic journey: He and his wife rowed from Monterey, Calif., to Hawaii to raise awareness of the dangers of sugar. During the 45 days it took to paddle across 2,700 miles of the Pacific, Zillow ( z ) agreed to acquire Trulia for $2.5 billion. Still a board member, Inkinen approved the sale via satellite phone.

Having sold the company and completed his physical quest, Inkinen was ready for a new mission. Im not a spiritual person, he says, but I knew I had to make this happen. After he met Dr. Stephen Phinney, the author of the paper that had convinced him that diet could solve his condition, a solution began to take shape in Inkinens mind.

Today Virtas service begins with an in-depth video session with a company doctor, who goes over each patients medical history and lifestyle to develop an eating strategy. Virta mails customers devices to record blood sugar, ketones (which indicate low insulin), and blood pressure. Patients enter data into the app, and a wireless scale automatically sends their weight to Virta. Each patient is then assigned a health coach, who monitors the data.

Users text their coaches daily via the app (some people prefer to call or use video chats). Advice gets granular. If a patient is planning to attend a birthday party, for example, her health coach could help develop an eating strategy beforehand.

Many patients are on medications when they begin the Virta program, and the goal is to slowly transition them off. Both meal recommendations and medications are constantly adjusted depending on what is, and isnt, having a positive effect on blood sugar, says Dr. Sarah Hallberg, the companys medical director.

Virta subscribes to a low-carb diet with moderate protein and fat, but its not doctrinaire. We accept any lifestyle and diet, says Inkinen. Instead of telling a person to swear off fast food, an often unrealistic option, health coaches recommend low-carb options on the menu. Physical activity is encouraged but not mandatory. You want someone to exercise when they come to you and say theyre ready, says Hallberg.

More: This Health Startup Plans to Challenge the Multibillion-Dollar Diet Industry

The service doesnt come cheap: It costs $400 a month (and isnt covered by insurance, though some employers health plans will reimburse for it). Virta has several thousand patients, according to Hallberg, served by about 20 health professionals.

The goal is to create a plan dramatic enough that it lowers blood sugar, but not so extreme that its unsustainable. In a clinical trial conducted in partnership with Indiana University Health, researchers found that 56% of the roughly 240 participants on the Virta platform lowered their blood sugar below diabetic levels by the end of the 10-week trial, and 87% no longer needed insulin.

Whether these results can be maintained is another question. The first couple of months of a diet are easy compared with an indefinite, fry-less future. Hallberg contends that the personalized support paired with the benefits of reduced medication and weight loss will keep people motivated despite the copious research establishing how hard most people find it to change their patterns.

Inkinen understands that as an endurance athlete he has more discipline (and capacity for suffering) than most people. His goal with Virta, as it was with Trulia, is to turn what was once a personal problem into a service that a large number of people can use. The stakes are higher this time around.

A version of this article appears in the July 1, 2017 issue of Fortune.

See more here:
Fighting Diabetes With Food - Fortune

Posted in Diabetes | Comments Off on Fighting Diabetes With Food – Fortune

Page 1,522«..1020..1,5211,5221,5231,524..1,5301,540..»